摘要
Source: Zhang H, Zhao W, Zhang X, et al. Efficacy and safety of ziresovir in hospitalised infants aged 6 months or younger with respiratory syncytial virus infection in China: findings from a phase 3 randomised trial with 24-month follow-up. Lancet Child Adolesc Health. 2025;9(5):325-336; doi: 10.1016/S2352-4642(25)00067-7.Investigators from multiple institutions conducted a randomized controlled trial assessing the efficacy and safety of ziresovir in children 1–24 months old with confirmed respiratory syncytial virus (RSV) infection who were hospitalized at 1 of 28 hospitals in China. The current study includes the results of a preplanned analysis of infants <6 months old who were enrolled in the trial. Eligibility criteria included a positive PCR for RSV and a Wang bronchiolitis clinical score (WBCS) of 35 at the time of administration of the first dose of study drug. The WBCS assesses respiratory rate, wheezing, retractions, and general condition using a 0–3 score for each component; higher scores are indicative of more severe disease. Study participants were randomized to receive ziresovir or placebo orally twice daily for 5 days. The study was conducted in 2 phases, with patients included in phase 1 assessed for safety and those in phase 2 evaluated for safety and efficacy. For those in phase 2, the primary outcome was change in WBCS from baseline to day 3. Secondary efficacy outcomes included change in viral load from baseline to day 5 and length of stay (LOS) following the first dose of study drug. The parents of infants in phase 2 were contacted up to 2 years after enrollment to collect data on subsequent episodes of wheezing in their children. Outcomes in participants randomized to ziresovir or placebo were compared with a variety of statistical tests. Drug-related, treatment-emergent, adverse events among patients in the 2 treatment groups also were compared.Data on 188 infants (125 in the ziresovir group and 63 randomized to placebo) were included in the safety analyses; 150 patients (100 randomized to ziresovir and 50 to placebo) were enrolled in the efficacy trial. The mean change in WBCS from baseline to day 3 was -3.5 points for children receiving ziresovir and -2.2 points for those in the placebo group (P = 0.0004). The reduction in viral load from baseline to day 5 was significantly greater in patients randomized to ziresovir than in placebo recipients (P = 0.024). There was no significant difference between groups for LOS. Drug-related, treatment-emergent, adverse events were reported in 22 (18%) children randomized to ziresovir and 7 (11%) of those randomized to placebo. The most common adverse event in ziresovir recipients was diarrhea, reported in 6 patients. Follow-up data were collected on 78 children who received ziresovir and 38 who were randomized to placebo. The annualized rates of wheeze in the 2 groups were 0.18 and 0.65 episodes, respectively (P = 0.005).The authors conclude that ziresovir had a positive clinical benefit, both in the immediate and long term, among infants <6 months old hospitalized for RSV.Dr Chang has disclosed no financial relationship relevant to this commentary. This commentary does not contain a discussion of an unapproved/investigative use of a commercial product/device.RSV infections are a leading cause of hospitalizations for young children, and infants <6 months of age are at higher risk for severe illness.1 In addition, previous investigators have found an association between infant RSV infections and future asthma development. (See AAP Grand Rounds. 2023;50[3]:27.)2 The authors of the current industry-sponsored study had previously reported that ziresovir, an orally administered RSV fusion protein inhibitor, was well tolerated and effectively reduced clinical signs and symptoms in hospitalized children aged 1–24 months with RSV. (See AAP Grand Rounds. 2025;53[1]:3.)3 The current study further characterized the efficacy of ziresovir for hospitalized children in the 1–6-month age group in the immediate period and during a longer-term follow-up of 2 years.The rigorous study design and methodology are notable strengths of this study, but study populations were small. While the WBCS was statistically lower in the ziresovir group compared to the placebo group, it is unclear whether the difference of 1.3 points between groups translates to clinically meaningful benefit. Similarly, while infants in the ziresovir group had lower rates of wheeze, wheeze was parent-reported and of unclear clinical significance, and a 2-year follow-up is insufficient to assess the incidence of asthma diagnoses. Though it remains to be seen whether ziresovir will be a clinically- and cost-effective treatment for RSV infections, this study presents an exciting therapeutic development, particularly for vulnerable, high-risk young infants.Oral ziresovir is a potentially promising new treatment for RSV infections in hospitalized young infants.Therapy of RSV infections is currently limited to aerosolized ribavirin for life-threatening infections in immunocompromised patients. The holy grail remains a safe and efficacious pediatric vaccine—now only available for pregnant women.4 No RSV vaccine is available for direct administration to infants. Thus, the results of this trial, especially if repeated in larger, ethnically diverse populations and in outpatient settings, suggest an oral antiviral—ziresovir—may be at least an interim chemotherapeutic option.